
usd may pm et
summari regeneron focus discoveri develop therapeut treat metabol
disord cancer inflammatori diseas respiratori condit
price-to-earnings oper ep
concentr sale eylea face
mount competit pressur howev
formid drug asset dupix
addit strong financi posit think
risk valu medium
fiscal year end dec ep estim base cfra
oper earn histor earn report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
rais
target reflect multipl
ep estim
ep vs
estim report revenu
billion increas yoy driven robust
sale dupix global net sale dupix
record sanofi increas
yoy million lower ep
reflect anticip
pressur eylea sale due
disrupt april partner sanofi
sni enter new agreement
praluent sni also continu
assess term collabor
kevzara develop patient
critic symptom also
develop prevent treat
viru oncolog
recent announc posit result libtayo
non-smal cell lung cancer advanc
basal cell carcinoma think lead
regulatori submiss
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview inc fulli integr biotechnolog
compani discov invent develop manufactur commerci medicin
treatment seriou diseas compani commerci medicin product candid
develop design help patient eye diseas allerg inflammatori diseas cancer
cardiovascular metabol diseas neuromuscular diseas infecti diseas rare diseas
regn core busi strategi maintain strong foundat basic scientif research
discovery-en technolog build foundat regn clinic develop
manufactur commerci capabl compani aim continu integr
multi-product biotechnolog compani provid patient medic profession import
option prevent treat human diseas
decemb market seven product eylea dupix praluent kevzara libtayo
arcalyst zaltrap eylea repres net product sale record
also reli partner collabor sell certain treatment certain geographi exampl
bayer record net product sale eylea outsid sanofi record global net product sale
dupix praluent kevzara zaltrap
competit landscap face substanti competit pharmaceut biotechnolog
chemic compani regn abil compet depend great extent fast develop safe
effect product candid complet clinic test approv process suppli
commerci quantiti product market competit among product candid approv
sale base efficaci safeti reliabl avail price patent posit factor
pipelin decemb product candid clinic develop
discov regn research laboratori
financi trend revenu grew billion reflect five-year compound annual
growth rate compound-annual-growth-rate adjust earn per share grew year-over-year reflect
five-year compound-annual-growth-rate typic maintain net cash posit gener billion
free cash flow defin oper cash flow less capit expenditur given compani
cash flow financi posit concern compani liquid abil
continu fund research develop effort
execut vice-president financ
chairman board
senior vice presid
senior vice presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
bullish sinc februari technic indic
bullish
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
spite global recess
concern posit outlook
histor defens sub-industri
expect see ramp-up new drug sale
continu develop mani new
innov therapi declin
preval patent expir
partli due govern shutdown
earli fda approv new drug
declin
fda approv shatter previou
record sinc novel approv set
new drug typic take least
year reach peak sale level mean
overal biotech industri like see
promis sale growth next year
addit think mani drug
either newli approv late-stag
clinic trial repres major advanc
treatment technolog gene therapi
zolgensma believ cure spinal
muscular atrophi one inject
expect impact larg
immateri suppli demand side
thing biotech firm although
firm industri could benefit
develop treatment vaccin sever
biotech firm work develop vaccin
treatment includ regeneron gilead
coverag warn investor
effect treatment vaccin often take
year develop difficult
determin whether treatment effect
prior gather signific amount
clinic data also expect substanti
price pressur treatment
commerci given urgent
widespread natur pandem
mean upsid success
treatment like minor
also impact biotech firm
clinic trial delay think
delay mostli immateri
near-term revenu long-term outlook
although deal count biopharmaceut
 lower
past decad total deal valu transact
billion largest amount
sinc accord evaluatepharma
total deal valu driven coupl
mega-d bristol-mey squibb
acquisit celgen
acquisit botox manufactur allergan
decemb biotech industri debt
level remain low rel histor level
rel industri addit
late march sub-industri valuat
sub-industri out-performance
lead us believ like
continu favor
environ biopharma
investor interest
biotechnolog stock mute high
drug price intens scrutini
 polit apparatu despit polit
littl happen neg impact
profit biotech firm dont
expect drug legisl come back
focu novemb
year-to-d march
biotechnolog index declin vs
declin composit
biotech index increas
rise valu
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
regn antibodi licens collabor agreement sanofi achiev
profit first time ahead expect regn profit share relat
antibodi agreement million vs loss million
prior-year period lift ep ep
revenu increas billion net product
sale expand billion sale recent launch dupix reach
million net product sale grew year-over-year
million encourag hear announc today phase trial
dupix children sever atop dermat met primari secondari
endpoint continu bullish pipelin /kevin huang cfa
pm et cfra keep buy opinion share
inc lower target base
ep ep vs lower
estim higher-than-expect expens cost
collabor contract manufactur expens yoy increas
 expens primarili attribut higher clinic trial
manufactur cost support wholli own program includ
new molecul light higher expect oper expens go
forward lower ep ep
sale key drug exceed expect across board
eylea sale increas billion libtayo second quarter
sale achiev million revenu dupix sale record
sanofi expand million continu favor view
regn robust pipelin recent launch product particularli
relat immuno-oncolog franchis /kevin huang cfa
analyst research note compani news
pm et cfra reiter hold opinion share regeneron
rais target
reflect multipl ep estim ep
vs estim report revenu
billion increas yoy driven robust sale dupix global net
sale dupix record sanofi increas yoy
million lower ep reflect anticip
pressur eylea sale due disrupt april partner
sanofi sni enter new agreement praluent sni also
continu assess term collabor kevzara
develop patient critic symptom also develop
prevent treat viru oncolog
recent announc posit result libtayo non-smal cell lung cancer
advanc basal cell carcinoma think lead regulatori
submiss indic /kevin huang cfa
pm et cfra lower opinion share
hold buy lift price target
reflect multipl ep estim lift ep
estim updat figur primarili
reflect recent present safeti concern drug beovu competitor
eylea potenti develop treatment
think recent share optim outweigh upsid opportun
associ risk nonetheless given stock recent upward
momentum due treatment optim think share
pm et cfra maintain buy opinion share regeneron
rais target price
reflect multipl ep estim ep
vs exceed estim due stronger-than-expect
sale growth driven dupix out-performance revenu increas
billion dupix sale record sanofi increas
yoy million full-year dupix sale billion
expect billion full-year eylea sale
pre-announc also exceed estim due modif
collabor agreement sanofi provid
guidanc later quarter rais ep
commenc ep see mani data regulatori
catalyst fda decis dupix patient
age expect may result phase studi dupix
pediatr patient asthma libtayo data two cancer /kevin huang
pm et cfra reiter buy opinion share regeneron
keep price target
reflect forward price-to-earnings multipl ep estim
ep vs surpass estim due
stronger-than-expect sale eylea dupix lift ep
revenu increas billion
eylea sale expand billion dupix global net sale grew
million provid posit updat libtayo
work establish first-lin therapeut non-smal cell lung
cancer studi enrol provid interim
analysi updat overal surviv today also announc
billion share repurchas program compani continu priorit
invest research capabl pipelin advanc manag feel
comfort enough strength balanc sheet long-term outlook
share repurchas well /kevin huang cfa
pm et cfra keep buy opinion share
inc lower price target base
ep ep vs beat
estim due higher-than-expect sanofi collabor revenu
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
